glutathione in parkinson's disease Enhanced accumulation of reduced by Scopoletin improves survivability of dopaminergic neurons model nebulized glutathione for parkinsons Levodopa

While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions

Longevity-focused patients

The products discussed are chemical reagents intended for laboratory research use only and are not intended for human use, diagnosis, treatment, cure, or prevention of any disease or medical condition

Advanced facial essences and ampoules